# ScreenPoint Medical

Source: https://onco.cc/companies/screenpoint-medical/  
OnCo record `screenpoint-medical` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Radboud University spin-out whose Transpara software is the AI reader tested in the MASAI screening trial.

## Summary

ScreenPoint's Transpara is CE-marked and FDA-cleared for 2D and 3D mammography and is the breast screening AI with the most published trial evidence, used in MASAI (Sweden) and in Danish and German programmes. The company's founders come from the Nijmegen computer-aided detection group that ran the DREAM mammography challenge.

## Fields

- Kind: Company
- Last checked: 2026-09-10
- HQ: Nijmegen
- Type: ai-software
- Website: https://screenpoint-medical.com

## Sources

- Official website: https://screenpoint-medical.com

## Connected records

- cancers: [HR-positive / HER2-negative breast cancer](https://onco.cc/cancers/breast-hr-positive/)
- fronts: [AI & Computation](https://onco.cc/fronts/ai-computation/), [Early Detection & Screening](https://onco.cc/fronts/early-detection/), [Imaging](https://onco.cc/fronts/imaging/)
- technologies: [AI in radiology](https://onco.cc/technologies/radiology-ai-screening/), [Mammography & tomosynthesis](https://onco.cc/technologies/mammography/)
- drugs: [Transpara](https://onco.cc/drugs/transpara/)
- trials: [MASAI (Mammography Screening with Artificial Intelligence)](https://onco.cc/trials/masai/)

---
JSON: https://onco.cc/api/v1/entities/screenpoint-medical.json